Strategic partnerships Leverage KaloCyte's Blue Knight collaboration with BARDA and JLABS to co-create joint development programs, supply agreements, or distribution partnerships for ErythroMer and related platforms in emergency and military medicine markets.

Supply chain readiness Position ErythroMer as a shelf-stable, lyophilized red blood cell substitute for remote or austere environments, healthcare facilities with limited blood supply, and disaster response agencies to address blood product shortages.

Health system integration Target hospital networks and trauma centers that value rapid, antigen-free transfusion options, offering integration with existing blood management and emergency response protocols to reduce cross-match requirements and improve availability.

Regulatory and funding leverage Highlight ongoing federal awards and DARPA-like funded programs to attract multi-year grant-to-commercialization funding opportunities, while exploring partnerships with government contractors for research, development, and scale-up.

Technology licensing Explore exclusive or co-exclusive licensing deals with biosynthetic hemoglobin producers and defense/health security players to accelerate production scale, reduce time-to-market, and expand geographic reach for ErythroMer and related oxygen-carrying technologies.